HFrEF Treatment: Therapies and Lifestyle Management

Treating heart failure with reduced ejection fraction (HFrEF) centers on a combination of four drug classes started together as early as possible, supplemented by devices, exercise-based rehabilitation, and careful lifestyle adjustments. This approach has transformed what was once a rapidly fatal condition into one that many people live with for years. But the science behind several long-held lifestyle recommendations, particularly around salt intake, has shifted in surprising ways, and getting all four medications on board at adequate doses remains a challenge that most patients never fully clear.

The Four-Pillar Drug Strategy

Current guidelines call for every HFrEF patient to be on four classes of medication unless there is a specific reason they cannot tolerate one. These are sometimes called the “four pillars” or “quadruple therapy,” and the goal is to get all four started early rather than adding them one at a time over months. A real-world study found that patients who failed to reach all four pillars at any dose had roughly double the risk of hospitalization or death compared with those who did.¹ Each class attacks the disease through a different pathway, and their benefits stack.

Renin-Angiotensin System Blockers and ARNIs

The oldest pillar is blocking the renin-angiotensin system, which drives harmful remodeling of the heart. For decades this meant ACE inhibitors or angiotensin receptor blockers (ARBs). A newer drug class called ARNIs (angiotensin receptor-neprilysin inhibitors) has largely replaced them. ARNIs combine an ARB with a neprilysin inhibitor, which boosts the body’s own protective hormones while blocking the harmful ones. A meta-analysis found that ARNIs cut cardiovascular death by about 29% and heart failure hospitalizations by about 22% compared with ACE inhibitors alone.² Patients with lower ejection fractions and younger patients appear to benefit even more.³ ARNIs also improve ejection fraction and quality-of-life scores more than ACE inhibitors do.⁴

Beta-Blockers

Heart failure drives the sympathetic nervous system into overdrive, flooding the heart with adrenaline-like signals that speed it up, demand more oxygen, and eventually damage the muscle further. Beta-blockers counter this by shielding the heart from chronic sympathetic stimulation, which slows the heart rate, improves how efficiently the muscle uses energy, and reverses some of the structural damage over time.⁵ Three specific beta-blockers have strong trial support in HFrEF: carvedilol, bisoprolol, and sustained-release metoprolol succinate. Not all beta-blockers are interchangeable here, so the specific choice matters.

Mineralocorticoid Receptor Antagonists

Spironolactone and eplerenone block aldosterone, a hormone that promotes fluid retention, scarring of the heart muscle, and inflammation. A large meta-analysis of randomized trials found that these drugs reduced cardiovascular death by about 23% and all-cause death by about 22% in HFrEF patients.⁶ A head-to-head comparison found that eplerenone was associated with even lower cardiovascular and all-cause mortality than spironolactone.⁷ Eplerenone also causes fewer hormonal side effects such as breast tenderness, which sometimes leads men in particular to discontinue spironolactone.

The main safety concern with these drugs is elevated potassium, which can become dangerous for patients whose kidneys do not clear it well. Newer potassium-binding agents such as patiromer can help. In one trial, patients on patiromer were more likely to tolerate full-dose spironolactone, potentially allowing more people to stay on this pillar.⁸

SGLT2 Inhibitors

Originally developed for diabetes, SGLT2 inhibitors (dapagliflozin and empagliflozin) turned out to reduce heart failure hospitalizations and cardiovascular death in HFrEF patients regardless of whether they have diabetes. How they accomplish this is still being pieced together. The leading theory involves effects at the kidney: SGLT2 inhibition causes the kidney to excrete more sodium and water, while also reducing pressure inside the kidney’s filtering units. That protects kidney function, which in turn lowers stress signals that worsen heart failure, including inflammation and excessive sympathetic nerve activity.⁹ Beyond the kidneys, SGLT2 inhibitors appear to improve how the heart remodels, reduce inflammation and oxidative stress, and shift the heart’s fuel source in ways that may make it more energy-efficient.¹⁰

Getting All Four Drugs On Board Quickly

For years, clinicians added one drug class at a time and titrated each to target dose before starting the next. This cautious approach meant many patients waited months to receive all four pillars, and some never got there at all. The current thinking favors starting all four early, even at low doses, because each class works through a different mechanism and the combined benefit begins accruing immediately. A single-center study comparing simultaneous initiation of all four classes against sequential introduction found that the simultaneous group had a significantly lower risk of heart failure hospitalization.¹¹

Real-world data confirms that the gap between guideline recommendations and actual practice remains wide. Many patients leave the hospital without all four classes prescribed, and those who do not achieve quadruple therapy face meaningfully worse outcomes.¹ The practical barriers are real: low blood pressure, kidney impairment, or high potassium can make each drug harder to tolerate. But the consensus has shifted toward starting all four at whatever doses the patient can handle, then up-titrating as tolerated, rather than perfecting one before adding the next.

Add-On Medications for Patients Still Struggling

Some patients remain symptomatic despite being on all four pillars. Two additional medications have evidence in this population.

Vericiguat works by boosting a signaling pathway (the nitric oxide pathway) that is impaired in heart failure, helping blood vessels relax and reducing the workload on the heart. In a large trial of patients with worsening heart failure, vericiguat reduced the combined risk of cardiovascular death or heart failure hospitalization by about 10% compared with placebo over roughly 11 months.¹² The benefit was modest, and the drug did not significantly reduce cardiovascular death on its own, but for patients who have already exhausted the core therapies, even incremental gains matter.

Ivabradine selectively slows the heart rate without affecting blood pressure, which makes it useful for patients whose heart rate stays above 70 beats per minute despite beta-blocker therapy. In the SHIFT trial, ivabradine cut the primary endpoint of cardiovascular death or heart failure hospitalization by 18%, driven mainly by a 26% reduction in hospitalizations for worsening heart failure.¹³

Device Therapies

When medications alone are not enough, implanted devices can address specific problems that drugs cannot fix.

Implantable Cardioverter-Defibrillators

Sudden cardiac death from a dangerous heart rhythm is a leading cause of death in HFrEF. Implantable cardioverter-defibrillators (ICDs) monitor the heart continuously and deliver a shock if a life-threatening arrhythmia occurs. They are recommended for primary prevention in patients whose ejection fraction remains at or below 35% despite optimal medical therapy.¹⁴ Despite the guideline recommendation, uptake remains low. A Swedish registry study found that only about 15% of eligible patients actually received one.¹⁵ Underuse reflects a mix of factors: patient preferences, clinician uncertainty about who benefits most, and the improving survival on modern drug regimens that may reduce sudden death risk enough to blunt the ICD’s added value for some patients.

Cardiac Resynchronization Therapy

In a substantial fraction of HFrEF patients, the left and right sides of the heart beat out of sync because electrical signals travel abnormally through the muscle. Cardiac resynchronization therapy (CRT) uses a special pacemaker to coordinate the contraction, which can reduce mortality, improve heart function, and relieve symptoms.¹⁶ The best candidates have a wide QRS complex on their electrocardiogram, particularly a left bundle branch block pattern. Even in patients with only mildly reduced ejection fractions, turning CRT on led to measurable improvements in heart function compared with CRT off.¹⁷ Many patients receive a combined CRT-defibrillator device that provides both resynchronization and sudden-death protection.

Transcatheter Mitral Valve Repair

Heart failure often stretches the mitral valve, allowing blood to leak backward with each beat. This worsens the already-struggling heart’s workload. A minimally invasive procedure can clip the valve leaflets together to reduce the leak. In the landmark COAPT trial, this approach cut the rate of heart failure hospitalizations roughly in half and reduced death from any cause by about 38% over two years compared with medical therapy alone.¹⁸ Follow-up at three years confirmed that the benefits were durable, with sustained improvements in quality of life and functional capacity.¹⁹ A subsequent trial in patients with moderate-to-severe mitral regurgitation showed similarly positive results, with quality-of-life scores improving by roughly 22 points (on a 100-point scale) in the device group versus 8 points with medical therapy alone.²⁰

Exercise and Cardiac Rehabilitation

For a long time, patients with HFrEF were told to rest and avoid exertion. That advice has been definitively overturned. Structured exercise training, typically delivered through a cardiac rehabilitation program that includes supervised aerobic activity, risk factor management, and psychosocial support, is now a core part of treatment.²¹ A systematic review and meta-analysis focused specifically on HFrEF patients found that exercise-based cardiac rehabilitation consistently improved exercise capacity and quality of life, though it has not been shown to reduce mortality or hospitalizations on its own.²²

The practical significance of improved exercise capacity should not be underestimated. Fatigue and breathlessness during daily activities are the symptoms that most degrade quality of life for people with heart failure. Being able to walk further, climb stairs, and carry groceries without stopping matters enormously even if it does not show up as a change in survival statistics. Most guidelines recommend starting with light aerobic activity three to five days per week and gradually increasing intensity, always under medical supervision during the initial phase.

The Sodium Debate

Few dietary recommendations in heart failure have been as persistently repeated, or as poorly supported by hard evidence, as strict salt restriction. For decades, patients were told to keep sodium intake well below 2,000 milligrams per day. The logic was straightforward: sodium promotes fluid retention, fluid retention worsens congestion, and congestion is the primary driver of heart failure symptoms. But that logic came largely from physiological reasoning and observations in untreated patients, not from clinical trials.

The SODIUM-HF trial randomized ambulatory heart failure patients to a low-sodium diet (targeting about 1,500 mg/day) or usual care. After 12 months, there was no significant difference in the combined outcome of death, cardiovascular hospitalization, or cardiovascular emergency visits.²³ A systematic review and meta-analysis pooling multiple randomized trials reached the same conclusion: sodium restriction did not reduce death, hospitalization, or the two combined.²⁴ One nuance from that review was that a moderate restriction (2,000 to 3,000 mg/day) showed a numerically lower risk of death compared with very strict restriction below 2,000 mg/day, suggesting that going too low may not help and could potentially cause harm.

European Society of Cardiology guidelines have responded by gradually softening the recommendation. The current stance advises limiting salt to no more than 5 grams per day (about 2,000 mg of sodium) while reserving fluid restriction of 1.5 to 2 liters per day only for selected patients with severe congestion.²⁵ The take-home message is not that sodium does not matter at all, but that the aggressive restrictions many patients have been following for years appear to offer no measurable clinical benefit and may reduce enjoyment of food without improving outcomes.

Remote Monitoring

Heart failure hospitalizations typically follow a period of rising pressures inside the heart and lungs that the patient cannot feel until symptoms become severe. By the time someone notices increased shortness of breath or weight gain, the hemodynamic worsening may have been building for days or weeks. Implantable pulmonary artery pressure monitors (the CardioMEMS system is the most studied) allow clinicians to track those pressures daily and adjust medications before symptoms spiral.

A meta-analysis of randomized trials found that remote pulmonary artery pressure monitoring reduced heart failure hospitalizations by about 28% to 33%, depending on how the outcome was measured.²⁶ A consensus statement from the European Heart Failure Association endorsed the approach, noting that daily pressure monitoring helps maintain clinical stability by keeping pressures in a target range on an ongoing basis.²⁷ The devices are not for everyone. They are most useful in patients who have already been hospitalized for heart failure and remain symptomatic despite optimal therapy, and they require an engaged care team that acts on the data.

When the Heart Needs More Than Medicine and Devices

For patients with advanced, end-stage HFrEF who remain severely limited despite everything described above, two options remain: heart transplantation and left ventricular assist devices (LVADs). Transplantation is the most effective therapy for advanced heart failure, but donor hearts are scarce. LVADs, mechanical pumps implanted inside the chest that help the weakened left ventricle push blood forward, have become a well-established alternative. They were originally intended as a temporary bridge while patients waited for a transplant, but they are now widely used as permanent (“destination”) therapy for patients who are not transplant candidates, improving both survival and quality of life.²⁸ The technology continues to improve, but complications including bleeding, infection, and stroke remain significant concerns that factor into the decision.

Iron Deficiency and Other Comorbidities

Iron deficiency affects roughly half of all heart failure patients, even many who are not technically anemic. It worsens fatigue, exercise intolerance, and overall function independently of hemoglobin levels. Intravenous iron replacement has been widely studied. In the HEART-FIT trial of ferric carboxymaltose, treated patients walked modestly further on a six-minute walk test at six months compared with placebo, though the improvement was small.²⁹ Earlier trials showed more robust improvements in symptoms and quality of life, making intravenous iron one of the more commonly recommended add-on treatments for iron-deficient heart failure patients. Screening for iron deficiency with a simple blood test is now standard practice.

Beyond iron, treating comorbidities that worsen heart failure, including atrial fibrillation, kidney disease, diabetes, sleep apnea, and depression, is a critical but sometimes overlooked part of management. Each of these conditions feeds back into the disease cycle, and leaving any of them undertreated limits what the core therapies can achieve.

Palliative Care Alongside Active Treatment

Palliative care in heart failure does not mean giving up on treatment. It means layering in symptom management, communication support, and psychosocial care alongside the disease-directed therapies. Studies have found that adding palliative care improves symptom control, quality of life, communication, and caregiver satisfaction while also reducing caregiver anxiety.³⁰ A systematic review of palliative care interventions for heart failure confirmed that most studies measuring patient-centered outcomes showed improvements, particularly in quality of life and patient satisfaction.³¹

The persistent misunderstanding that palliative care is only for the dying keeps many patients from receiving it early enough. Heart failure’s unpredictable trajectory, with periods of stability punctuated by acute deteriorations, makes advance care planning especially important. Having honest conversations about goals, preferences, and what-if scenarios during a stable period is far better than navigating those questions during a crisis hospitalization.

Who Gets Optimal Treatment and Who Does Not

One of the most frustrating aspects of HFrEF care is how unevenly guideline-recommended therapies are actually delivered. Globally, women, uninsured patients, and people in low- and middle-income countries are consistently less likely to be on target doses of recommended medications.³² In the United States, patients without private insurance and those with identified social needs such as food insecurity, housing instability, or transportation barriers scored significantly lower on measures of guideline therapy optimization.³³

Even when medications are prescribed, adherence is another hurdle. Patients living in lower-income neighborhoods had nonadherence rates above 50%, compared with about 40% in the most affluent neighborhoods, and the odds of not filling prescriptions were roughly 57% higher in the lowest-income quartile.³⁴ This is not primarily a knowledge or motivation problem. The medications involved in quadruple therapy can be expensive, and managing four or more drugs with dose titration visits, lab monitoring, and potential side effects requires time, transportation, and a stable living situation that not everyone has. Addressing these structural barriers is as important as developing the next new molecule.